Atlas Trials

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants

Clinical trial NCT03536325 · COMPLETED

Trial details

NCT number
NCT03536325
Sponsor
Janssen Pharmaceutical K.K.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Healthy
Start date
2018-05-31
Primary completion
2018-10-25
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.